Clearmind Medicine Granted Divisional Patent Approval in China for Psychedelic Treatment
DENVER, Colo., Mar 19, 2024 (247marketnews.com)- Clearmind Medicine Inc. (NASDAQ:CMND) stated, this morning, that it received divisional patent approval by the China National Intellectual Property Administration, granting Clearmind a broader claim than a previously announced patent application.
“We are proud to receive once again recognition of our innovative treatment for binge behaviors. We believe that this approval is a major milestone and significantly expands our IP protection as a leader in psychedelic-derived therapeutics,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. “In various pre-clinical studies, carried out during the past 2 years, MEAI has demonstrated its ability to regulate binge behaviors, addiction and other mental health disorders. We believe these strong results demonstrate the significant potential of the MEAI molecule for various indications.”
For further CMND commentary, please click here.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (CMND)
- Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
- 24/7 Market News Snapshot 03 July, 2025 – Clearmind Medicine Inc. Common Shares (NASDAQ:CMND)
- MoBot alert highlights: NASDAQ: CMND, NASDAQ: LRHC, NASDAQ: THTX, NASDAQ: WINT, NASDAQ: EMPG (07/03/25 08:00 AM)
- Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
- Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics